Pharma

Your Article Summary

See Latest Articles

Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
Takeda Pharmaceuticals North America, 08/31/09

Takeda Pharmaceutical Company Limited and Takeda Global Research and Development Center, Inc., a wholly owned United States subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration has agreed to the study design for a cardiovascular outcomes trial titled EXAMINE for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09

Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials
The Lancet - Early Online Publication, 12/01/09

 See all of Drug Trials